Alpha Tau Medical (NASDAQ:DRTS) CFO Raphi Levy Sells 17,730 Shares of Stock

Alpha Tau Medical Ltd. (NASDAQ:DRTS) CFO Raphi Levy sold 17,730 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $14.00, for a total transaction of $248,220.00. Following the transaction, the chief financial officer owned 90,180 shares in the company, valued at approximately $1,262,520. The trade was a 16.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raphi Levy also recently made the following trade(s):

• On Monday, July 6th, Raphi Levy sold 2,270 shares of Alpha Tau Medical stock. The shares were sold at an average price of $14.00, for a total transaction of $31,780.00.
• On Thursday, July 2nd, Raphi Levy sold 17,873 shares of Alpha Tau Medical stock. The stock was sold at an average price of $13.00, for a total transaction of $232,349.00.
• On Wednesday, July 1st, Raphi Levy sold 2,127 shares of Alpha Tau Medical stock. The stock was sold at an average price of $13.02, for a total transaction of $27,693.54.
• On Tuesday, June 30th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The stock was sold at an average price of $12.00, for a total transaction of $240,000.00.
• On Thursday, June 25th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The shares were sold at an average price of $11.00, for a total transaction of $220,000.00.
• On Tuesday, June 23rd, Raphi Levy sold 17,500 shares of Alpha Tau Medical stock. The shares were sold at an average price of $9.55, for a total value of $167,125.00.
• On Wednesday, June 3rd, Raphi Levy sold 32,500 shares of Alpha Tau Medical stock. The stock was sold at an average price of $10.83, for a total value of $351,975.00.

Alpha Tau Medical Stock Down 2.8%

Shares of Alpha Tau Medical stock opened at $13.87 on Thursday. The business’s 50 day simple moving average is $11.75 and its 200 day simple moving average is $9.27. Alpha Tau Medical Ltd. has a 52-week low of $3.00 and a 52-week high of $14.40. The firm has a market cap of $1.25 billion, a PE ratio of -13.34 and a beta of 1.17. The company has a debt-to-equity ratio of 0.09, a quick ratio of 7.79 and a current ratio of 7.79.

Alpha Tau Medical (NASDAQ:DRTS) last released its earnings results on Monday, August 10th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.36). The business had revenue of $0.10 million during the quarter, compared to analysts’ expectations of $0.14 million. On average, analysts predict that Alpha Tau Medical Ltd. will post -0.67 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Everhart Financial Group Inc. acquired a new stake in shares of Alpha Tau Medical in the second quarter valued at approximately $126,000. Renaissance Technologies LLC bought a new stake in shares of Alpha Tau Medical in the first quarter valued at approximately $286,000. Principal Financial Group Inc. acquired a new stake in Alpha Tau Medical during the first quarter worth approximately $132,000. Millennium Management LLC grew its position in Alpha Tau Medical by 185.7% during the fourth quarter. Millennium Management LLC now owns 107,815 shares of the company’s stock worth $534,000 after buying an additional 70,081 shares in the last quarter. Finally, Mariner LLC increased its stake in Alpha Tau Medical by 1.6% during the 4th quarter. Mariner LLC now owns 125,165 shares of the company’s stock worth $620,000 after acquiring an additional 1,915 shares during the period. 2.65% of the stock is owned by institutional investors.

Key Headlines Impacting Alpha Tau Medical

Here are the key news stories impacting Alpha Tau Medical this week:

• Positive Sentiment: HC Wainwright raised its price target on Alpha Tau Medical to $16 from $15 and reiterated a “Buy” rating. The target implies approximately 15% upside from the referenced $13.87 price, providing a positive catalyst for DRTS. HC Wainwright raises Alpha Tau Medical price target
• Positive Sentiment: Investor interest has helped push DRTS to a new 12-month high, with market coverage highlighting the potential for further appreciation under HC Wainwright’s bullish outlook. Alpha Tau Medical sets new 12-month high

Wall Street Analysts Forecast Growth

DRTS has been the subject of a number of research analyst reports. Benchmark restated a “buy” rating on shares of Alpha Tau Medical in a report on Thursday, July 23rd. HC Wainwright increased their target price on Alpha Tau Medical from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Tuesday. Piper Sandler lifted their price target on Alpha Tau Medical from $5.00 to $8.00 and gave the stock a “neutral” rating in a report on Tuesday, May 19th. LADENBURG THALM/SH SH boosted their price target on Alpha Tau Medical from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alpha Tau Medical in a report on Friday, July 17th. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Alpha Tau Medical presently has a consensus rating of “Moderate Buy” and an average target price of $12.80.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.